NCT07071831 RETRO Study (RETrograde Renal Access Outcomes)
| NCT ID | NCT07071831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Renal Stones |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-12-06 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-12-06 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the benefit of using RetroPerc® in obtaining renal access for percutaneous nephrolithotomy. The device is already used in routine clinical practice by urologists around the country. Participants who are already scheduled to undergo percutaneous nephrolithotomy as part of their regular care will be asked to participate.
Eligibility Criteria
Inclusion Criteria: * Renal stone or total linear sum of 1.5-3cm cm in maximum dimension (largest diameter in axial or coronal)--- multiple stones should be summed to determine stone size. * Age \>=18 years of age * Gender: both men and women included. * Ethnic background: all ethnicities will be included in the study population and the specific ethnic diversity present in the study population will reflect the geographic distributions of the participating institutions. * Plan for PCNL in the supine position Exclusion Criteria: * Active pregnancy * BMI \>45 * Severe Hydronephrosis - renal pelvis diameter \> 20mm * Flank window \< 4 cm are ineligible for puncture * Previous ipsilateral PCNL * Currently with "useful" nephrostomy tube on ipsilateral side * Uncorrectable coagulopathies * Untreated urinary tract infection * Subjects with significant morbidities such as American Society of Anesthesiologists (ASA) score ≥ 4, severe spinal cord injuries, severe cardiopulmonary insufficiency, uncontrolled diabetes, neurological disorders, bedbound, anticipated life expectancy less than 5 years, or any other comorbidity, that in the opinion of the principal investigator could represent an increased peri-operative risk for the subject; * Ipsilateral partial nephrectomy * History of ipsilateral ureteral reimplantation or ureteral reconstruction; * History of Simple or radical prostatectomy * History of cystectomy * History of calyceal diverticula stone; * History of renal donation or transplant; * Any other previous pelvic surgical treatment that could put the subject at greater procedural complication risk or technical difficulty; * Ureteral ipsilateral stricture, untreated; * Ureteral stricture, untreated (not to include "tight" ureter); * Any other bladder, ureteral or kidney congenital genitourinary abnormalities (e.g. Horseshoe kidney, ipsilateral duplicated or partially duplicated collecting system, ipsilateral ectopic kidney, cross-fused ectopia, bifid renal pelvis with no horizontally directed calyces, solitary kidney, etc.) preventing the ability to direct a puncture laterally or render the subject stone free; * Have participated in any other clinical trial within the last 3 months, and/or plans to participate in any other investigational or invasive clinical trial during this study; * If female, breast-feeding, or if childbearing age, is not using contraception between screening and 90 days post-op; * Subject has current or recent history of substance abuse (e.g. recreational drugs, narcotics, or alcohol) requiring intervention; * Is a prisoner or ward of the state; * Is unable to meet the treatment and follow up protocol requirements.
Contact & Investigator
Bristol Whiles, MD
PRINCIPAL INVESTIGATOR
University of Kansas Medical Center
Frequently Asked Questions
Who can join the NCT07071831 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Stones. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07071831 currently recruiting?
Yes, NCT07071831 is actively recruiting participants. Contact the research team at jledesma2@kumc.edu for enrollment information.
Where is the NCT07071831 trial being conducted?
This trial is being conducted at Tampa, United States, Kansas City, United States.
Who is sponsoring the NCT07071831 clinical trial?
NCT07071831 is sponsored by University of Kansas Medical Center. The principal investigator is Bristol Whiles, MD at University of Kansas Medical Center. The trial plans to enroll 150 participants.